Clinical Trial: Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07047755) titled 'Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC' on June 19.

Brief Summary: This is a prospective, open-label, phase II study evaluating the efficacy and safety of Trastuzumab Rezetecan in combination with pertuzumab in early or locally advanced HER2-positive breast cancer.

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: Trastuzumab Rezetecan

Trastuzumab Rezetecan

DRUG: Pertuzumab

Pertuzumab

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Henan Cancer Hospital

Information provided by (Responsible Party): Zhenzhen Liu, Henan Cancer Hos...